Tower Research Capital LLC TRC raised its position in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 148.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,254 shares of the biotechnology company’s stock after acquiring an additional 5,525 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Axon Enterprise were worth $2,391,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the company. Sands Capital Management LLC lifted its stake in Axon Enterprise by 0.6% in the fourth quarter. Sands Capital Management LLC now owns 2,628,652 shares of the biotechnology company’s stock worth $679,060,000 after acquiring an additional 16,347 shares during the last quarter. Wellington Management Group LLP lifted its stake in Axon Enterprise by 3.3% in the third quarter. Wellington Management Group LLP now owns 1,956,022 shares of the biotechnology company’s stock worth $389,229,000 after acquiring an additional 62,324 shares during the last quarter. Norges Bank purchased a new position in Axon Enterprise in the fourth quarter worth approximately $195,406,000. Westfield Capital Management Co. LP lifted its stake in Axon Enterprise by 5.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 731,721 shares of the biotechnology company’s stock worth $189,025,000 after acquiring an additional 35,528 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Axon Enterprise by 3.1% in the third quarter. Northern Trust Corp now owns 631,212 shares of the biotechnology company’s stock worth $125,605,000 after acquiring an additional 19,068 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Axon Enterprise Stock Up 0.5 %
AXON stock opened at $280.50 on Friday. The company has a fifty day moving average price of $299.72 and a 200 day moving average price of $278.24. Axon Enterprise, Inc. has a 12 month low of $175.37 and a 12 month high of $329.87. The company has a market cap of $21.17 billion, a price-to-earnings ratio of 82.02 and a beta of 0.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. Axon Enterprise’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 EPS. Sell-side analysts expect that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.
Insider Buying and Selling at Axon Enterprise
In other Axon Enterprise news, Director Jeri Williams sold 308 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the transaction, the director now directly owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Axon Enterprise news, insider Jeffrey C. Kunins sold 43,668 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.94, for a total value of $13,534,459.92. Following the transaction, the insider now directly owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeri Williams sold 308 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the transaction, the director now directly owns 1,607 shares in the company, valued at $498,282.49. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,447 shares of company stock valued at $27,684,677. 6.10% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on AXON. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Robert W. Baird boosted their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 22nd. JMP Securities restated a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a research report on Tuesday, May 7th. Craig Hallum boosted their price objective on shares of Axon Enterprise from $325.00 to $370.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $335.27.
Read Our Latest Report on Axon Enterprise
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
